What is Nanobiotix?
Headquartered in Paris with a robust presence in Cambridge, Massachusetts, Nanobiotix is a pioneer in the development of disruptive, physics-based therapeutic approaches. Since its inception in 2003, the company has focused on revolutionizing treatment outcomes for patients, particularly in the oncology space. By utilizing nanotechnology to enhance the efficacy of radiotherapy, the firm aims to redefine standard-of-care protocols. Listed on both Euronext Paris and the Nasdaq Global Select Market, Nanobiotix maintains a dual-market presence that facilitates access to both European and North American institutional investors, reflecting its status as a global leader in innovative medical technology.
How much funding has Nanobiotix raised?
Nanobiotix has raised a total of $281.3M across 4 funding rounds:
Debt
$11.3M
Stock Offering
$99M
Other Financing Round
$71M
Stock/Share Issuance
$100M
Debt (2020): $11.3M with participation from Bpifrance and HSBC
Stock Issuance/Offering (2020): $99M led by Undisclosed
Other Financing Round (2025): $71M supported by HealthCare Royalty Management
Stock/Share Issuance (2026): $100M, investors not publicly disclosed
Key Investors in Nanobiotix
Bpifrance
A French public investment bank that provides comprehensive financial support to companies at every stage of development through credit, guarantees, and equity.
HSBC
A global banking and financial services organization that facilitates international trade and capital flows through an extensive network spanning six continents.
HealthCare Royalty Management
A specialized investment firm focused on providing non-dilutive capital solutions to biopharmaceutical companies by acquiring royalty interests in commercial-stage assets.
What's next for Nanobiotix?
With the recent injection of $100M, Nanobiotix is well-positioned to accelerate its late-stage clinical trials and strengthen its commercial infrastructure. The strategic focus will likely shift toward finalizing pivotal data readouts and preparing for potential market entry in key jurisdictions. By maintaining a lean operational model supported by non-dilutive capital and strategic partnerships, the company is poised to translate its scientific breakthroughs into tangible patient benefits. Future growth will be dictated by the successful integration of its therapeutic candidates into existing clinical workflows, further cementing its role as a transformative force in the biopharmaceutical industry.
See full Nanobiotix company page
